Developments in the therapeutic applications of bisphosphonates

被引:42
作者
Brown, DL [1 ]
Robbins, R [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Div Endocrinol & Metab, New York, NY 10021 USA
关键词
D O I
10.1177/00912709922008272
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The authors review the structural, pharmacologic, and clinical aspects of bisphosphonates, a class of drugs currently used to treat several disorders of bone and calcium metabolism. Pertinent literature on the bisphosphonates was reviewed with the help of a MEDLINE search and several bibliographies, including published clinical trials, monographs, and review articles. The bisphosphonates are analogs of pyrophosphate that, when given orally or intravenously, bind avidly to exposed bone mineral and disrupt bone turnover. These agents comprise three groups or generations, based an their potency and chemical structures. All three generations are effective in treating hypercalcemia, Paget's disease of bone, osteoporosis, and other disorders of accelerated bone turnover. The third-generation agents have the greatest potency and offer the promise of a convenient way to suppress or prevent osseous metastasis in patients with certain malignancies. As a group, these agents are well tolerated and, when administered correctly, rarely cause toxicity. The bisphosphonates are safe and effective agents for the treatment of disorders of accelerated bane turnover. (C) 1999 the American College of Clinical Pharmacology.
引用
收藏
页码:651 / 660
页数:10
相关论文
共 57 条
  • [1] EFFECTS OF ORAL ALENDRONATE AND INTRANASAL SALMON-CALCITONIN ON BONE MASS AND BIOCHEMICAL MARKERS OF BONE TURNOVER IN POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS
    ADAMI, S
    PASSERI, M
    ORTOLANI, S
    BROGGINI, M
    CARRATELLI, L
    CARUSO, I
    GANDOLINI, G
    GNESSI, L
    LAURENZI, M
    LOMBARDI, A
    NORBIATO, G
    PRYORTILLOTSON, S
    REDA, C
    ROMANINI, L
    SUBRIZI, D
    WEI, L
    YATES, AJ
    [J]. BONE, 1995, 17 (04) : 383 - 390
  • [2] [Anonymous], BISPHOSPHONATES BONE
  • [3] Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
    Berenson, JR
    Lichtenstein, A
    Porter, L
    Dimopoulos, MA
    Bordoni, R
    George, S
    Lipton, A
    Keller, A
    Ballester, O
    Kovacs, MJ
    Blacklock, HA
    Bell, R
    Simeone, J
    Reitsma, DJ
    Heffernan, M
    Seaman, J
    Knight, RD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (08) : 488 - 493
  • [4] Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
    Black, DM
    Cummings, SR
    Karpf, DB
    Cauley, JA
    Thompson, DE
    Nevitt, MC
    Bauer, DC
    Genant, HK
    Haskell, WL
    Marcus, R
    Ott, SM
    Torner, JC
    Quandt, SA
    Reiss, TF
    Ensrud, KE
    [J]. LANCET, 1996, 348 (9041) : 1535 - 1541
  • [5] TREATMENT OF TUMOR-INDUCED HYPERCALCEMIA WITH THE BISPHOSPHONATE PAMIDRONATE - DOSE-RESPONSE RELATIONSHIP AND INFLUENCE OF TUMOR TYPE
    BODY, JJ
    DUMON, JC
    [J]. ANNALS OF ONCOLOGY, 1994, 5 (04) : 359 - 363
  • [6] Body JJ, 1997, CANCER, V80, P1699, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1699::AID-CNCR23>3.3.CO
  • [7] 2-A
  • [8] Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: A randomized trial
    Boutsen, Y
    Jamart, J
    Esselinckx, W
    Stoffel, M
    Devogelaer, JP
    [J]. CALCIFIED TISSUE INTERNATIONAL, 1997, 61 (04) : 266 - 271
  • [9] BOYCE BF, 1984, LANCET, V1, P821
  • [10] ALENDRONATE TREATMENT OF THE POSTMENOPAUSAL OSTEOPOROTIC WOMAN - EFFECT OF MULTIPLE DOSAGES ON BONE MASS AND BONE REMODELING
    CHESTNUT, CH
    MCCLUNG, MR
    ENSRUD, KE
    BELL, NH
    GENANT, HK
    HARRIS, ST
    SINGER, FR
    STOCK, JL
    YOOD, RA
    DELMAS, PD
    KHER, U
    PRYORTILLOTSON, S
    SANTORA, AC
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 99 (02) : 144 - 152